"Novartis' Lutathera® Shows 72% Risk Reduction in Advanced Neuroendocrine Tumors"
Novartis presented data from the Phase III NETTER-2 trial at the 2024 ASCO Gastrointestinal Cancers Symposium, showing that Lutathera plus octreotide LAR significantly reduced the risk of disease progression or death by 72% as a first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study confirmed the clinical benefit of first-line radioligand therapy for newly diagnosed patients with advanced GEP-NETs, addressing a significant unmet need. The trial is ongoing for further evaluation of secondary endpoints including overall survival and long-term safety.
